Literature DB >> 6978196

Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.

J D Poland, C H Calisher, T P Monath, W G Downs, K Murphy.   

Abstract

Previous studies on the duration of antibody following vaccination with 17D yellow fever (17D YF) virus vaccine have indicated that immunity persists for at least 17 years and suggest that the vaccine may provide lifelong immunity. We studied sera obtained from 149 veterans of the Second World War, 30 - 35 years after military service during which YF vaccination was required for defined groups. A significantly high proportion of "vaccinated" subjects was found to be seropositive to 17D YF virus. The highest proportion of seropositive "vaccinated" veterans (97%) was among navy and air corps personnel, while only 60% of "vaccinated" army personnel and 19% of "unvaccinated" personnel were seropositive. This study suggests that (i) antibody to 17D YF virus, as measured by the plaque-reduction neutralization test (PRNT), persists for 30 years or more following administration of a potent vaccine; (ii) army personnel often had not received potent vaccine, even though their service history indicated that they should have been vaccinated; (iii) some personnel were vaccinated, although their service did not include vaccination-designated areas; and (iv) 88% of veterans with persistent PRNT antibody to 17D YF virus also had mouse-protective antibody against French neurotropic YF virus.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6978196      PMCID: PMC2396120     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  3 in total

1.  Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine.

Authors:  E C ROSENZWEIG; R W BABIONE; C L WISSEMAN
Journal:  Am J Trop Med Hyg       Date:  1963-03       Impact factor: 2.345

2.  Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine.

Authors:  H GROOT; R B RIBERIRO
Journal:  Bull World Health Organ       Date:  1962       Impact factor: 9.408

3.  Yellow fever vaccination in Malaya by subcutaneous injection and multiple puncture. Neutralizing antibody responses in persons with and without pre-existing antibody to related viruses.

Authors:  C E SMITH; L H TURNER; P ARMITAGE
Journal:  Bull World Health Organ       Date:  1962       Impact factor: 9.408

  3 in total
  113 in total

1.  Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile Virus infection.

Authors:  G Tardei; S Ruta; V Chitu; C Rossi; T F Tsai; C Cernescu
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response.

Authors:  R G van Der Most; K Murali-Krishna; R Ahmed; J H Strauss
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Yellow Fever Immunizations: Indications and Risks.

Authors:  Mary E. Wilson; Lin H. Chen; Elizabeth D. Barnett
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

4.  Mapping the risk of yellow Fever infection.

Authors:  David R Hill
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

5.  Yellow fever vaccine seroconversion in travelers.

Authors:  Allison Kay; Lin H Chen; Maggie Sisti; Thomas P Monath
Journal:  Am J Trop Med Hyg       Date:  2011-10       Impact factor: 2.345

6.  Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.

Authors:  Rex Biedenbender; Joan Bevilacqua; Anne M Gregg; Mike Watson; Gustavo Dayan
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

7.  Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?

Authors:  M A Martins; M L Silva; A P V Marciano; V Peruhype-Magalhães; S M Eloi-Santos; j G L Ribeiro; R Correa-Oliveira; A Homma; E G Kroon; A Teixeira-Carvalho; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

8.  Antibody to dengue 1 detected more than 60 years after infection.

Authors:  Allison Imrie; Janet Meeks; Alexandra Gurary; Munkhzul Sukhbaatar; Thang Thua Truong; C Bruce Cropp; Paul Effler
Journal:  Viral Immunol       Date:  2007-12       Impact factor: 2.257

Review 9.  Optimal delivery of vaccines: clinical pharmacokinetic considerations.

Authors:  S Gizurarson
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

10.  Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins.

Authors:  Eddie A James; Rebecca E LaFond; Theresa J Gates; Duy T Mai; Uma Malhotra; William W Kwok
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.